Antagonism by ketanserin of the behavioral effects of quipazine but not l-5-hydroxytryptophan in squirrel monkeys

[1]  E. sanders-Bush,et al.  Additional evidence that l-5-hydroxytryptophan discrimination models a unique serotonin receptor , 2004, Psychopharmacology.

[2]  E. sanders-Bush,et al.  Discriminative stimulus properties of l-5-hydroxytryptophan: Behavioral evidence for multiple serotonin receptors , 2004, Psychopharmacology.

[3]  J. Barrett,et al.  Effects of serotonin receptor agonists and antagonists on schedule-controlled behavior of squirrel monkeys. , 1985, The Journal of pharmacology and experimental therapeutics.

[4]  J. Barrett,et al.  Effects of serotonin receptor antagonists on punished responding maintained by stimulus-shock termination or food presentation in squirrel monkeys. , 1985, The Journal of pharmacology and experimental therapeutics.

[5]  D. Mokler,et al.  The 5HT2 antagonist pirenperone reverses disruption of FR-40 by hallucinogenic drugs , 1985, Pharmacology Biochemistry and Behavior.

[6]  K. Cunningham,et al.  Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD. , 1985, European journal of pharmacology.

[7]  E. sanders-Bush,et al.  Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites. , 1984, The Journal of pharmacology and experimental therapeutics.

[8]  R. Ortmann.  The 5‐HT syndrome in rats as tool for the screening of psychoactive drugs , 1984 .

[9]  I. Lucki,et al.  Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. , 1984, The Journal of pharmacology and experimental therapeutics.

[10]  D. Reis,et al.  Some neurons of the rat central nervous system contain aromatic-L-amino-acid decarboxylase but not monoamines. , 1983, Science.

[11]  C. Niemegeers,et al.  A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. , 1982, The Journal of pharmacology and experimental therapeutics.

[12]  J. Leander.  Antagonism by methysergide of the effects of l-5-hydroxytryptophan and quipazine on schedule-controlled responding , 1981, Neuropharmacology.

[13]  S. Snyder,et al.  Two distinct central serotonin receptors with different physiological functions. , 1981, Science.

[14]  J. Leysen,et al.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. , 1981, Life sciences.

[15]  R. Fuller.  Pharmacology of central serotonin neurons. , 1980, Annual review of pharmacology and toxicology.

[16]  F. J. White,et al.  Discriminative stimulus properties of quipazine: Direct serotonergic mediation , 1979, Neuropharmacology.

[17]  R. B. Carter,et al.  Role of peripheral mechanisms in the behavioral effects of 5-hydroxytryptophan , 1978, Pharmacology Biochemistry and Behavior.

[18]  K. Davis.  Psychopharmacology: A Biochemical and Behavioral Approach , 1978 .

[19]  F. J. White,et al.  Discriminative stimulus properties of quipazine , 1977, Neuropharmacology.

[20]  L. Seiden,et al.  Psychopharmacology: A Biochemical and Behavioral Approach , 1977 .

[21]  T. Chase,et al.  Release of [3H]dopamine byl-5-hydroxytryptophan , 1972 .

[22]  T. Chase,et al.  Release of ( 3 H)dopamine by L-5-hydroxytryptophan. , 1972, Brain research.

[23]  D. Straughan,et al.  Excitation and depression of cortical neurones by 5‐hydroxytryptamine , 1967, The Journal of physiology.

[24]  L. N. Balaam,et al.  Biostatistics -- An Introductory Text , 1965 .

[25]  N H AZRIN,et al.  An apparatus for delivering pain shock to monkevs. , 1963, Journal of the experimental analysis of behavior.